Evidence map›Paper›PMID 41250824›Full record

ArticleDiabetes, obesity & metabolism2026

The value and impact of weight reduction from the perspective of people with type 2 diabetes in the United States.

Melissa M Ross, Sarah Mulnick, Kristina S Boye, Ashley Samuelson, Vivian Thuyanh Thieu, Christine Longuet, Jennifer Glass, Meredith M Hoog

Abstract read
In one paragraph

Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Melissa M RossThermo Fisher Scientific, Waltham, Massachusetts, USA.ORCID 0000-0001-7317-9273
Sarah MulnickThermo Fisher Scientific, Waltham, Massachusetts, USA.
Kristina S BoyeEli Lilly and Company, Indianapolis, Indiana, USA.
Ashley SamuelsonThermo Fisher Scientific, Waltham, Massachusetts, USA.
Vivian Thuyanh ThieuEli Lilly and Company, Indianapolis, Indiana, USA.ORCID 0000-0001-9803-4134
Christine LonguetEli Lilly Canada, Toronto, Ontario, Canada.
Jennifer GlassEli Lilly Canada, Toronto, Ontario, Canada.
Meredith M HoogEli Lilly and Company, Indianapolis, Indiana, USA.

Funding

Eli Lilly and Company
6 · The paper itself

Abstract

aimsTo understand the importance and potential impacts of reaching a lower weight or body mass index (BMI) from the perspectives of people with type 2 diabetes (T2D) across BMI levels. MATERIALS AND

methodsA cross-sectional survey, informed by qualitative interviews, was administered to a sample representative of the US T2D population by BMI. The survey asked about experience and perceptions of weight management, the impact of T2D on quality of life (QoL), and the value of 5%, 10%, and 20% weight reductions. Results were summarised descriptively.

resultsAmong 388 participants (54% male; 10% Hispanic; 90% White; mean age 61 years [SD: 13]; mean self-reported BMI 32.7 kg/m

conclusionsPeople with T2D, across BMI categories, place considerable value on the opportunity for weight reduction yet endure considerable challenges in doing so through lifestyle interventions, even when weight reduction is discussed with their healthcare provider.

Indexed as

Diabetes Mellitus, Type 2ObesityQuality of LifeWeight LossAgedBody Mass IndexCross-Sectional StudiesFemaleHumansMaleMiddle AgedUnited StatesWeight Reduction Programsbarrierspatient‐reported outcomestype 2 diabetesweight controlweight management

Identifiers

PMID41250824
PMCPMC12803662

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.